AstraZeneca's Tagrisso Doublet Therapy Shows 49% Response Rate In Lung Cancer Setting

AstraZeneca Plc AZN has reported preliminary results from the SAVANNAH Phase 2 trial of Tagrisso (osimertinib) plus savolitinib in epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with high levels of MET overexpression and/or amplification, whose disease progressed on Tagrisso.
Tagrisso plus savolitinib demonstrated an objective response rate (ORR) of 49%.
The highest ORR was observed in patients with high levels of MET who were not treated with prior chemotherapy (52%).
In patients whose tumors did not show high levels of MET, the ORR was 9%.
Savolitinib, marketed in China under Orpathys, is an oral, potent, and highly selective MET tyrosine kinase inhibitor (TKI) jointly developed and commercialized by AstraZeneca and HUTCHMED (China) Ltd HCM.
The safety profile of Tagrisso plus savolitinib was consistent with the known profiles of the combination and each treatment alone. No new safety signals were identified.
The global SAFFRON Phase 3 trial will further assess the Tagrisso plus savolitinib combination versus platinum-based doublet chemotherapy in patients with EGFRm, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC following Tagrisso.
Price Action: AZN shares are down 0.44% at $65.74 during the premarket session on the last check Monday.